Summary

Blood Tumor, also known as hematological disease, is a type of cancer impacting bone marrow, blood, and lymph nodes. Different sorts of mature blood cells include white blood cells for immune protection, platelets for wound clotting, and red blood cells to carry oxygen. In the bone marrow, it originates from progenitor cells and hematopoietic stem. Hematologic malignancies initiate in these cells and are subcategorized as per the type of blood cell that is affected such as myeloid or myelogenous or and lymphocytic lymphoblastic. A malignancy in the lymphoid lineage involves B lymphocytes and T lymphocytes. Malignancy in the myeloid lineage involves precursor cells to white blood cells platelets and red blood cells.

Market Analysis and Insights: Global Blood Tumor Treatment Market
The global Blood Tumor Treatment market is projected to grow from US$ 1964 million in 2024 to US$ 3195.4 million by 2030, at a Compound Annual Growth Rate (CAGR) of 8.5% during the forecast period.
have been significant developments in targeted therapies that specifically attack cancer cells without harming healthy cells, leading to improved treatment outcomes and reduced side effects.
Immunotherapies, including CAR T-cell therapies, have shown promising results in treating certain types of blood cancers, driving interest and investment in this area.
Continued investments in research and development have led to the discovery of new treatment approaches and drugs, expanding the treatment options available for patients.

Report Covers:
This report presents an overview of global market for Blood Tumor Treatment market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Blood Tumor Treatment, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Blood Tumor Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Blood Tumor Treatment revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Blood Tumor Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Blood Tumor Treatment revenue, projected growth trends, production technology, application and end-user industry.

Market Segmentation
By Company
Bristol-Myers Squibb
Johnson & Johnson
AbbVie
Novartis
Roche
Amgen
Takeda
Pfizer
AstraZeneca
Gilead Sciences
Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy
Other
Segment by Application
Leukemia
Lymphoma
Multiple Myeloma
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Blood Tumor Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Blood Tumor Treatment companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Blood Tumor Treatment revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Blood Tumor Treatment Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy
1.2.5 Other
1.3 Market by Application
1.3.1 Global Blood Tumor Treatment Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Leukemia
1.3.3 Lymphoma
1.3.4 Multiple Myeloma
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Blood Tumor Treatment Market Perspective (2019-2030)
2.2 Global Blood Tumor Treatment Growth Trends by Region
2.2.1 Blood Tumor Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Blood Tumor Treatment Historic Market Size by Region (2019-2024)
2.2.3 Blood Tumor Treatment Forecasted Market Size by Region (2025-2030)
2.3 Blood Tumor Treatment Market Dynamics
2.3.1 Blood Tumor Treatment Industry Trends
2.3.2 Blood Tumor Treatment Market Drivers
2.3.3 Blood Tumor Treatment Market Challenges
2.3.4 Blood Tumor Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Blood Tumor Treatment by Players
3.1.1 Global Blood Tumor Treatment Revenue by Players (2019-2024)
3.1.2 Global Blood Tumor Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Blood Tumor Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Blood Tumor Treatment, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Blood Tumor Treatment Market Concentration Ratio
3.4.1 Global Blood Tumor Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Blood Tumor Treatment Revenue in 2023
3.5 Global Key Players of Blood Tumor Treatment Head office and Area Served
3.6 Global Key Players of Blood Tumor Treatment, Product and Application
3.7 Global Key Players of Blood Tumor Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Blood Tumor Treatment Breakdown Data by Type
4.1 Global Blood Tumor Treatment Historic Market Size by Type (2019-2024)
4.2 Global Blood Tumor Treatment Forecasted Market Size by Type (2025-2030)
5 Blood Tumor Treatment Breakdown Data by Application
5.1 Global Blood Tumor Treatment Historic Market Size by Application (2019-2024)
5.2 Global Blood Tumor Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Blood Tumor Treatment Market Size (2019-2030)
6.2 North America Blood Tumor Treatment Market Size by Type
6.2.1 North America Blood Tumor Treatment Market Size by Type (2019-2024)
6.2.2 North America Blood Tumor Treatment Market Size by Type (2025-2030)
6.2.3 North America Blood Tumor Treatment Market Share by Type (2019-2030)
6.3 North America Blood Tumor Treatment Market Size by Application
6.3.1 North America Blood Tumor Treatment Market Size by Application (2019-2024)
6.3.2 North America Blood Tumor Treatment Market Size by Application (2025-2030)
6.3.3 North America Blood Tumor Treatment Market Share by Application (2019-2030)
6.4 North America Blood Tumor Treatment Market Size by Country
6.4.1 North America Blood Tumor Treatment Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Blood Tumor Treatment Market Size by Country (2019-2024)
6.4.3 North America Blood Tumor Treatment Market Size by Country (2025-2030)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Blood Tumor Treatment Market Size (2019-2030)
7.2 Europe Blood Tumor Treatment Market Size by Type
7.2.1 Europe Blood Tumor Treatment Market Size by Type (2019-2024)
7.2.2 Europe Blood Tumor Treatment Market Size by Type (2025-2030)
7.2.3 Europe Blood Tumor Treatment Market Share by Type (2019-2030)
7.3 Europe Blood Tumor Treatment Market Size by Application
7.3.1 Europe Blood Tumor Treatment Market Size by Application (2019-2024)
7.3.2 Europe Blood Tumor Treatment Market Size by Application (2025-2030)
7.3.3 Europe Blood Tumor Treatment Market Share by Application (2019-2030)
7.4 Europe Blood Tumor Treatment Market Size by Country
7.4.1 Europe Blood Tumor Treatment Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Blood Tumor Treatment Market Size by Country (2019-2024)
7.4.3 Europe Blood Tumor Treatment Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Blood Tumor Treatment Market Size (2019-2030)
8.2 China Blood Tumor Treatment Market Size by Type
8.2.1 China Blood Tumor Treatment Market Size by Type (2019-2024)
8.2.2 China Blood Tumor Treatment Market Size by Type (2025-2030)
8.2.3 China Blood Tumor Treatment Market Share by Type (2019-2030)
8.3 China Blood Tumor Treatment Market Size by Application
8.3.1 China Blood Tumor Treatment Market Size by Application (2019-2024)
8.3.2 China Blood Tumor Treatment Market Size by Application (2025-2030)
8.3.3 China Blood Tumor Treatment Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Blood Tumor Treatment Market Size (2019-2030)
9.2 Asia Blood Tumor Treatment Market Size by Type
9.2.1 Asia Blood Tumor Treatment Market Size by Type (2019-2024)
9.2.2 Asia Blood Tumor Treatment Market Size by Type (2025-2030)
9.2.3 Asia Blood Tumor Treatment Market Share by Type (2019-2030)
9.3 Asia Blood Tumor Treatment Market Size by Application
9.3.1 Asia Blood Tumor Treatment Market Size by Application (2019-2024)
9.3.2 Asia Blood Tumor Treatment Market Size by Application (2025-2030)
9.3.3 Asia Blood Tumor Treatment Market Share by Application (2019-2030)
9.4 Asia Blood Tumor Treatment Market Size by Region
9.4.1 Asia Blood Tumor Treatment Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Blood Tumor Treatment Market Size by Region (2019-2024)
9.4.3 Asia Blood Tumor Treatment Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Blood Tumor Treatment Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Blood Tumor Treatment Market Size by Type
10.2.1 Middle East, Africa, and Latin America Blood Tumor Treatment Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Blood Tumor Treatment Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Blood Tumor Treatment Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Blood Tumor Treatment Market Size by Application
10.3.1 Middle East, Africa, and Latin America Blood Tumor Treatment Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Blood Tumor Treatment Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Blood Tumor Treatment Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Blood Tumor Treatment Market Size by Country
10.4.1 Middle East, Africa, and Latin America Blood Tumor Treatment Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Blood Tumor Treatment Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Blood Tumor Treatment Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Details
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Blood Tumor Treatment Introduction
11.1.4 Bristol-Myers Squibb Revenue in Blood Tumor Treatment Business (2019-2024)
11.1.5 Bristol-Myers Squibb Recent Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Blood Tumor Treatment Introduction
11.2.4 Johnson & Johnson Revenue in Blood Tumor Treatment Business (2019-2024)
11.2.5 Johnson & Johnson Recent Developments
11.3 AbbVie
11.3.1 AbbVie Company Details
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Blood Tumor Treatment Introduction
11.3.4 AbbVie Revenue in Blood Tumor Treatment Business (2019-2024)
11.3.5 AbbVie Recent Developments
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Blood Tumor Treatment Introduction
11.4.4 Novartis Revenue in Blood Tumor Treatment Business (2019-2024)
11.4.5 Novartis Recent Developments
11.5 Roche
11.5.1 Roche Company Details
11.5.2 Roche Business Overview
11.5.3 Roche Blood Tumor Treatment Introduction
11.5.4 Roche Revenue in Blood Tumor Treatment Business (2019-2024)
11.5.5 Roche Recent Developments
11.6 Amgen
11.6.1 Amgen Company Details
11.6.2 Amgen Business Overview
11.6.3 Amgen Blood Tumor Treatment Introduction
11.6.4 Amgen Revenue in Blood Tumor Treatment Business (2019-2024)
11.6.5 Amgen Recent Developments
11.7 Takeda
11.7.1 Takeda Company Details
11.7.2 Takeda Business Overview
11.7.3 Takeda Blood Tumor Treatment Introduction
11.7.4 Takeda Revenue in Blood Tumor Treatment Business (2019-2024)
11.7.5 Takeda Recent Developments
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Blood Tumor Treatment Introduction
11.8.4 Pfizer Revenue in Blood Tumor Treatment Business (2019-2024)
11.8.5 Pfizer Recent Developments
11.9 AstraZeneca
11.9.1 AstraZeneca Company Details
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Blood Tumor Treatment Introduction
11.9.4 AstraZeneca Revenue in Blood Tumor Treatment Business (2019-2024)
11.9.5 AstraZeneca Recent Developments
11.10 Gilead Sciences
11.10.1 Gilead Sciences Company Details
11.10.2 Gilead Sciences Business Overview
11.10.3 Gilead Sciences Blood Tumor Treatment Introduction
11.10.4 Gilead Sciences Revenue in Blood Tumor Treatment Business (2019-2024)
11.10.5 Gilead Sciences Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details